Bispecific Antibodies to Threaten Multiple Myeloma Cell Therapy in the US in 2023

pharma4.globaldata.com/Analysis/TableOfContents/Bispecific-Antibodies-to-Threaten-Multiple-Myeloma-Cell-Therapy-in-the-US-in-2023

Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia

academic.oup.com/brain/article/139/12/3057/2630009

Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies

www.ncbi.nlm.nih.gov/pmc/articles/PMC5580514/

Structure of Pathological TDP-43 Filaments From ALS With FTLD

www.ncbi.nlm.nih.gov/pmc/articles/PMC7612255/

Targeting TDP-43 Proteinopathy With Drugs and Drug-Like Small Molecules

bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.15148

Towards a TDP-43-Based Biomarker for ALS and FTLD

link.springer.com/article/10.1007/s12035-018-0947-6

Borrowing CAR-T tool from cancer therapy, lupus patients go into remission

www.statnews.com/2022/09/15/lupus-patients-remission-car-t-therapy/

ChatGPT Is Just a Tree I...

twitter.com/itsPaulAi/status/1653394472854495232

B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools

www.frontiersin.org/articles/10.3389/fmed.2022.952304/full

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

ard.bmj.com/content/81/1/100

FDA Agrees to Early Trial of KYV-101, Cell Therapy for Lupus Nephritis

lupusnewstoday.com/news/fda-oks-phase-1-trial-kyv-101-cell-therapy-lupus-nephritis/

Best way of organizing Ableton?

www.reddit.com/r/ableton/comments/oj4ayt/best_way_of_organizing_ableton/

I searched through over 100+ AI tools this week

twitter.com/rowancheung/status/1651248526964187136

Targeting CD22 for the Treatment of B-Cell Malignancies

www.ncbi.nlm.nih.gov/pmc/articles/PMC8275043/

The Landscape of CAR T-Cell Therapy in the United States and China: A Comparative Analysis

onlinelibrary.wiley.com/doi/full/10.1002/ijc.31924

R&D Strategies in the Lupus Market

pharma4.globaldata.com/Analysis/TableOfContents/R-D-Strategies-in-the-Lupus-Market

Anti-Cd19 CAR T Cell Therapy for Refractory Systemic Lupus Erythematosus

www.nature.com/articles/s41591-022-02017-5

Systemic Lupus Erythematosus: Major Drug Trials to Watch in 2022 and 2023

www.clinicaltrialsarena.com/analysis/lups-clinical-trials/

Alzheimer's Disease Facts and Figures

www.alz.org/alzheimers-dementia/facts-figures

Chimeric Antigen Receptor (CAR) T-Cell Therapy for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

pubmed.ncbi.nlm.nih.gov/34515338/

Autolus Therapeutics unveils expanded next generation technology and pipeline and provides key update on AUTO3 program in pediatric ALL at R&D Day

pharma3.globaldata.com/News/Autolus-Therapeutics-unveils-expanded-next-generation-technology-and-pipeline-and-provides-key-update-on-AUTO3-program-in-pediatric-ALL-at-R-D-Day--

Feed post

www.linkedin.com/feed/update/urn:li:activity:7052215114531246080/

ViewPoint - GlobalData Intelligence Center - Pharma

pharma3.globaldata.com/Analysis/TableOfContents/CD19-CAR-T-Agents-Expected-to-Treat-Over-13-000-Patients-Annually-by-2031

The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview

www.ncbi.nlm.nih.gov/pmc/articles/PMC7563774/

The Emerging Landscape of Alternative Pathway Complement Inhibitors

www.ajmc.com/view/the-emerging-landscape-of-alternative-pathway-complement-inhibitors

Unlock the Power of ChatGPT to Revolutionize Your Investment Approach

www.vcstack.io/blog/unlock-the-power-of-chatgpt-to-revolutionize-your-investment-approach

Venture Capital vs. Angel Investing Processes

www.vcstack.io/blog/venture-capital-vs-angel-investing-processes#vc-investment-process

Synthetic Short-Chain Peptide Analogues of H1 Relaxin Lack Affinity for the RXFP1 Receptor and Relaxin-Like Bioactivity. Clues to a Better Understanding of Relaxin Agonist Design - PubMed

pubmed.ncbi.nlm.nih.gov/36034864/

Effects of Serelaxin in Patients With Acute Heart Failure | NEJM

www.nejm.org/doi/full/10.1056/NEJMoa1801291

Effects of Serelaxin in Patients With Acute Heart Failure.

www.wizdom.ai/publication/10.1056/NEJMOA1801291/title/effects_of_serelaxin_in_patients_with_acute_heart_failure

The Incidence of All-Cause, Cardiovascular and Respiratory Disease Admission Among 20,252 Users of Lisinopril vs. Perindopril: A Cohort Study

pubmed.ncbi.nlm.nih.gov/27362832/

MetaGeneBank: A Standardized Database to Study Deep Sequenced Metagenomic Data From Human Fecal Specimen

bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-021-02321-z

Drug View - GlobalData Intelligence Center - Pharma

pharma5.globaldata.com/DrugsView/ProductView?ProductId=13275&ProductType=0,1

Sample Size Calculation

www.ncbi.nlm.nih.gov/pmc/articles/PMC2876926/

Wikiwand - Zymergen

www.wikiwand.com/en/Zymergen

Effects of serelaxin in patients admitted for acute heart failure: a meta‐analysis

onlinelibrary.wiley.com/doi/10.1002/ejhf.1692

RA Capital | Careers

open-positions.racap.com/?company=raventure

Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions

www.ncbi.nlm.nih.gov/pmc/articles/PMC8085397/

580.pdf

watermark-silverchair-com.ep.fjernadgang.kb.dk/580.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAs8wggLLBgkqhkiG9w0BBwagggK8MIICuAIBADCCArEGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMZSugL3ow7v3sUFoaAgEQgIICghNT26L4N26qHRlw01xQfhuiRfXE5vZTY4oYwkmrFkMJmsKz7M6f9oAXPajYlkihMuVxh9Mo1a726KyBkFupnb-yRzK4yaW8IV8xuPWzrooWiEIBcJPPSr49yTfArvy4VxHCIXdWrPsT60ZC5h-f7RGITMjQiWChUMBO4D1wuXbJZvIcroAmF5AGO6EKk1G3ZRrPtENUKRuzNs60MmzNYFnnI590TQTIzlVeKKhkgYSmqt_iG5bbKZ0e1sPwzub0ArpS7fMhgoZUQldLBDhZrvT8doui0cqOvC3FWvJDl_b3Hrt6Sb0fPAhPGWnejr84wB3lAkksH-XXqudpD1wlcJtrLBjaWu1B-owWDbsXAAczCdJ_G16-PJb58k_HyyJzm7zOgxZGm__jU_rUBtC6y9k74dY_U-sYMEfVI7QtZ24Gc0GOY5ByWDOYeid0_XENdVrpSvWZ7MZA8eMkZc4hutekM4Wg8styiwKWZQqneX71IIReQCC96ziFhUum-mIGdfOTzJg8CzGLKr9bnmtwDPCBOsM0nl1-V00hocqte60InTr2K7-0t_Jy34J5Tfx0uVqj9Hg59gS9jLQJia12kkAtqdBVkVtq11sY1bNfpyUavHNeNMMEjgIe90qYmZg-pS9koWwQTyJUb2-D3nKdQaUMY_mOv8o-mpNKENtnA_teoVSEAhCpk_MSWciMmlnpYjPCL-xnx1-pb8HQ8Opw_nLN4xjzaJ6I5OD7IpM42YZrdL-nR16uEYT5SmQki2xlvwre0akmYd9Mag6-OIV1eclsEiw7iehZuOFeDRhJmsACwgXanZilnge-5Djz4bbuKjPb54QeyFNK6ri3HfpyWr7S2A

beta.clinicaltrials.gov/study/NCT03518112?tab=results

beta.clinicaltrials.gov/study/NCT03518112?tab=table